Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement

This document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.

Downloads

Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Last updated:
Publication type:
Report
Audience:
General public
Language:
English
Description:

This document summarises the Chief Medical Officer's consideration of Alexion Pharmaceuticals Australasia Pty Ltd's application to include asfotase alfa (Strensiq®) on the Life Saving Drugs Program for the treatment of peri-natal and infantile onset hypophosphatasia.

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.